Human granulocytic ehrlichiosis in Estonia.To the Editor: We report a case of a 24-year-old woman living in a rural area of Estonia who had weakness, chills, and diarrhea on May 10, 2002 On day 5 of the illness, she was admitted to the Department of Infectious Diseases, University of Tartu At different times during its history the University of Tartu was known as Academia Gustaviana, University of Dorpat, '' Universität (zu) Dorpat, University of Yuryev, and Tartu State University (Tartu Riiklik Ülikool)''. , with high fever (38.5 [degrees] C) and muscle pains throughout her body Examination showed mild jaundice painful and enlarged liver, and inability to move. Throat was erythematous, and enlarged lymph nodes enlarged lymph nodes Lymphadenopathy, see there were palpable on the neck. Laboratory findings included the following: leukopenia leukopenia /leu·ko·pe·nia/ (-pe´ne-ah) reduction of the number of leukocytes in the blood below about 5000 per cubic mm.leukope´nic basophilic leukopenia basophilopenia. 2.04x[10.sup.9]/L; erythrocytes 4.08x[10.sup.12]/L; hemoglobin 130 g/L; thrombocytopenia 36x[10.sup.9]/L; eosinophils Eosinophils A leukocyte with coarse, round granules present. Mentioned in: Histiocytosis X eosinophils 0%; basophils 1.0%; monocytes monocytes, n.pl the largest of the white blood cells. They have one nucleus and a large amount of grayish-blue cytoplasm. Develop into macrophages and both consume foreign material and alert T cells to its presence. 7.5%; lymphocytes 38.0%; neutrophils 51.0%; reactive lymphcytes 2.0%; plasma cells 0.5%; C-reactive protein 38 mg/L (normal <5 mg/L); bilirubin 95 [micro]mol/L (normal <17 [micro]mol/L); aspartate aminotransferase 121 U/L (normal <31 U/L); alanine aminotransferase 108 UL (normal <31 U/L); and alcaline phosphatase 200 U/L (normal 35-104 U/L). Ehrlichiosis was suspected by clinical symptoms and leukopenia, thrombocytopenia, and elevated transaminases. Human granulocytic ehrlichiosis human granulocytic ehrlichiosis: see ehrlichiosis. (HGE HGE hemorrhagic gastroenteritis. ) is an emerging tick-borne disease described for the first time in 1994 in the United States (l). The first European case of HGE was reported in Slovenia in 1996 (2). Infection with Ehrlichia phagocytophila, the agent of HGE, occurs in areas endemic for Borrelia burgdorferi (3). In Estonia, Lyme borrreliosis is frequently diagnosed in humans but the occurrence of ehrlichiosis has not been established for this region, despite our having found some seropositive results in Lyme borrreliosis patients (4). This case of ehrlichiosis is the first diagnosed in Estonia. The initial diagnosis was based on a typical clinical spectrum of symptoms and clinical laboratory findings, which are relatively nonspecific, making the diagnosis problematic (5). Polymerase chain reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is results for Ehrlichia were negative, and we did not find morula morula /mor·u·la/ (mor´u-lah) 1. the solid mass of blastomeres formed by cleavage of a zygote. 2. an inclusion body seen in circulating leukocytes in ehrlichiosis. in the blood smear. Indirect immunofluorescence assay (IFA Immunofluorescent assay (IFA) A blood test sometimes used to confirm ELISA results instead of using the Western blotting. In an IFA test, HIV antigen is mixed with a fluorescent compound and then with a sample of the patient's blood. , MRL Diagnostics, Cypress, CA) was used as a confirmatory serologic test. However, results of this assay are often negative during the initial phase of the disease (5,6). On day 7 of illness, the serologic results for immunoglobulin (Ig) M type antibodies to Ehrlichia were positive (1:20) and negative for IgG. The diagnosis of ehrlichiosis was established, and therapy with doxycycline was started. After 4 days, the patient became afebrile afebrile /afe·brile/ (a-feb´ril) without fever. a·feb·rile adj. Apyretic. afebrile without fever. afebrile adjective Feverless , and on day 6 she left for home. One month later, the titers of both types of antibodies to Ehrlichia were increased: IgM titer was 1:160 and IgG titer was 1:128; 6 months later, IgM antibodies were negative, and the IgG titer remained unchanged. Our patient had a typical spectrum of clinical and laboratory changes to Ehrlichia, but not very specific findings of infection with E. phagocytophila. The results of IFA, i.e., IgM antibodies in the beginning of the disease and increasing titer of IgG antibodies during the course of the disease, confirmed the diagnosis. Granulocytic granulocytic pertaining to granulocytes. granulocytic leukemia see myelocytic leukemia. granulocytic sarcoma extramedullary growth of multiple, focal granulocytic neoplasm. They may be neutrophilic or eosinophilic. ehrlichiosis should be considered in patients with tick-associated fever. References (1.) Bakken JS, Dumler S, Chert SM, VanEtta LL, Eckman MR, Walker DH. Human granulocytic ehrlichiosis in the United States: a new species emerging? JAMA JAMA abbr. Journal of the American Medical Association 1994;272:212-8. (2.) Petrovec M, Lotric-Furlan S, Avsic-Zupanc T, Strle F, Brouqui P, Roux V, et al. Human disease in Europe caused by a granulocytic Ehrlichia species. J Clin Microbiol 1997;35:1556-9. (3.) Bjoersdorff A, Wittesjo B, Berglund I, Massung RF, Eliasson I. Human granulocytic ehrlichiosis as a common cause of tick-associated fever in Southeast Sweden: report from a prospective clinical study. Scand J Infect Dis 2002;34:187-91. (4.) Prukk T, Nilsson I, Bjoersdorff A, Wadstrom T. Seroprevalence of ehrlichiosis in south-Estonia. Budapest: First Congress of the European Society for Emerging Infections; 1998. (5.) Lotric-Furlan S, Avsic-Zupanc T, Petrovec M, Nicholson WL, Sumner JW, Childs JE, et al. Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia. Clin Diagn Lab Immunol 2001;8:899-903. (6.) Olano JP, Walker DH. Human ehrlichioses: diagnostic challenges and therapeutic recommendations. Infect Med 2002;19: 318-25. Address for correspondence: T. Prukk, Department of Infectious Diseases, University of Tartu, Lina 6,51004, Tartu, Estonia; fax: 372 7 374232; email tiinap@cut.ee Tiina Prukk, * Kylliki Ainsalu, [dagger] Ene Laja, [double dagger] and Ada Aigro [double dagger] * University of Tartu, Tartu, Estonia; [dagger] Internal Medicine Clinic of Tartu University, Tartu, Estonia [double dagger] United Laboratories of Tartu University Clinics, Tartu, Estonia [double dagger] United Laboratories of Tartu University Clinics, Tartu, Estonia |
|
||||||||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion